DEPARTMENT OF GENERAL, VASCULAR, ENDOCRINE AND TRANSPLANT SURGERY, MEDICAL UNIVERSITY OF WARSAW, WARSAW, POLAND.
NEPHROLOGY, DIALYSIS AND INTERNAL MEDICINE, WARSAW MEDICAL UNIVERSITY, WARSAW, POLAND.
Wiad Lek. 2024;77(9):1769-1774. doi: 10.36740/WLek/193211.
Abdominal Aortic Aneurysm (AAA) represents a signif i cant global health issue with a high risk of rupture, resulting in substantial mortality rates. Endovascular Aneurysm Repair (EVAR) has emerged as the preferred treatment method due to its minimally invasive nature. However, the procedure carries a risk of acute kidney injury (AKI), particularly post-contrast acute kidney injury (PC-AKI), which can adversely af f ect patient outcomes. This review examines the incidence, pathophysiology, and prevention strategies for PC-AKI in the context of EVAR. It synthesizes current research on the mechanisms underlying PC-AKI, such as renal vasoconstriction, oxidative stress, and tubular toxicity. The ef f ectiveness of various preventive measures, including pre-procedural hydration, use of low-osmolality contrast agents, and alternative imaging techniques, is evaluated. Additionally, the review explores patient-specif i c risk factors and the potential of novel pharmacologic interventions. The incidence of PC-AKI in EVAR varies based on procedural complexity and patient-specif i c factors like preexisting renal insuf f i ciency, diabetes, and hypertension. Preventive strategies such as intravenous hydration and the use of less nephrotoxic contrast agents have shown ef f ectiveness. Advances in imaging technology and innovative pharmacologic interventions, including antioxidants and vasodilatory drugs, present promising approaches to reducing the risk of PC-AKI. Ef f ective management of PC-AKI in EVAR necessitates a comprehensive and multifaceted approach that considers both procedural and patient-specif i c factors. Future research should aim to standardize diagnostic criteria, ref i ne preventive strategies, and explore novel therapies. Enhanced understanding of PC-AKI pathophysiology and personalized preventive measures can improve patient safety and outcomes in EVAR procedures.
腹主动脉瘤 (AAA) 是一个重大的全球健康问题,具有很高的破裂风险,导致死亡率很高。血管内动脉瘤修复术 (EVAR) 因其微创性而成为首选治疗方法。然而,该手术有发生急性肾损伤 (AKI) 的风险,特别是对比剂后急性肾损伤 (PC-AKI),这会对患者的预后产生不利影响。本综述探讨了 EVAR 中 PC-AKI 的发生率、病理生理学和预防策略。它综合了目前关于 PC-AKI 机制的研究,如肾血管收缩、氧化应激和肾小管毒性。评估了各种预防措施的有效性,包括术前水化、使用低渗透压对比剂和替代成像技术。此外,该综述还探讨了患者特定的危险因素和新型药物干预的潜力。EVAR 中 PC-AKI 的发生率取决于手术复杂性和患者特定因素,如预先存在的肾功能不全、糖尿病和高血压。静脉补液和使用肾毒性较小的对比剂等预防策略已被证明有效。成像技术的进步和创新的药物干预,包括抗氧化剂和血管扩张剂,为降低 PC-AKI 的风险提供了有前途的方法。EVAR 中 PC-AKI 的有效管理需要综合考虑手术和患者特定因素的全面和多方面的方法。未来的研究应旨在标准化诊断标准、改进预防策略并探索新的治疗方法。对 PC-AKI 病理生理学的深入了解和个性化预防措施可以提高 EVAR 手术的患者安全性和结果。